SCHEMBL13290407

SCHEMBL13290407

CC(=O)N(C)[C@H]1CC[C@H](C(=O)Nc2c(C(=O)Nc3ccc(Cl)cn3)oc3cccnc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ F10 P00742 5/20 0.41
▸ TP53 P04637 4/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ TSHR P16473 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ DEGS1 O15121 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422919 0.93 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL4277151 0.93 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL2950956 0.92 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL2950971 0.92 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL13290499 0.91 F10 (0.43) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL13290562 0.89 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL2953282 0.89 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL2953281 0.89 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL13290442 0.89 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AF10TP53
SCHEMBL13290417 0.87 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AF10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885MEN1 1453/4885KMT2A 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback